A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer

Molecular Oncology

Volumn 9, Issue 1, 2015, Pages 115-127

  Vollan, Hans Kristian Moen ^a,b,c   Rueda, Oscar M ^a   Chin, Suet Feung ^a   Curtis, Christina ^a,d   Turashvili, Gulisa ^e,f   Shah, Sohrab P ^e,f   Lingjærde, Ole Christian ^c,g   Yuan, Yinyin ^a,p   Ng, Charlotte K ^q   Dunning, Mark J ^a   Dicks, Ed ^h   Provenzano, Elena ^i,j   Sammut, Stephen J ^j   McKinney, Steven ^e,f   Ellis, Ian O ^k   Pinder, Sarah ^a,l,m   Purushotham, Arnie ^a,l,m   Murphy, Leigh C ⁿ   Kristensen, Vessela N ^b,c,o   Brenton, James D ^a,i,j   Pharoah, Paul D P ^a,i,j   Børresen Dale, Anne Lise ^b,c   Aparicio, Samuel ^e,f   Caldas, Carlos ^a,i,j   Huntsman, David ^a,e,f   Bardwell, Helen ^a   Ding, Zhihao ^a   Gräf, Stefan ^a   Jones, Linda ⁱ   Liu, Bin ^a   Lynch, Andy G ^a   Papatheodorou, Irene ^a   Wishart, Gordon ^j   Chia, Steven ^f   Gelmon, Karen ^f   Speers, Caroline ^f   Watson, Peter ^e,f,n   Blamey, Roger ^k   Green, Andrew ^k   Macmillan, Douglas ^k   Rakha, Emad ^k   Gillett, Cheryl ^l   Grigoriadis, Anita ^l   di Rinaldis, Emanuele ^l   Tutt, Andy ^l   Parisien, Michelle ⁿ   Troup, Sandra ⁿ   Chan, Derek ^a   Fielding, Claire ^a   Maia, Ana Teresa ^a   McGuire, Sarah ^a   Osborne, Michelle ^a   Sayalero, Sara M ^a   Spiteri, Inmaculada ^a   Hadfield, James ^a   Bell, Lynda ^f,t   Chow, Katie ^f,t   Gale, Nadia ^f,t   Kovalik, Maria ^f,t   Ng, Ying ^f,t   Prentice, Leah ^f,t   Tavaré, Simon ^a,r,s   Russell, Roslin ^a   Samarajiwa, Shamith ^a   Speed, Doug ^a,r   Markowetz, Florian ^a   Bashashati, Ali ^e,t   Ha, Gavin ^e,t   Haffari, Gholamreza ^e,t   more..

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f Canadian Centre for Applied Research in Cancer Control   (Canada)

^g UNIVERSITY OF OSLO   (Norway)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁱ Cambridge Experimental Cancer Medicine Centre   (United Kingdom)

^j ADDENBROOKE S HOSPITAL   (United Kingdom)

^k UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^l KING'S COLLEGE LONDON   (United Kingdom)

^m GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

ⁿ UNIVERSITY OF MANITOBA   (Canada)

^o AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^p INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^q MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^r UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^s UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^t BRITISH COLUMBIA CANCER AGENCY   (Canada)

more..

Author keywords

Biomarker; Breast cancer; DNA copy number; Genomic instability; Genomics; Ovarian cancer; Prognostic markers

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGEN DNA INTERACTION; CHROMOSOME 8P; CHROMOSOME REARRANGEMENT; COMPLEX ARM WISE ABERRATION INDEX; ESTROGEN RECEPTOR NEGATIVE BREAST CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENE DOSAGE; GENE EXPRESSION; GENOMIC INSTABILITY; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PREDICTOR VARIABLE; PROGRESSION FREE SURVIVAL; SCORING SYSTEM; VALIDATION STUDY; BREAST TUMOR; CHROMOSOME ABERRATION; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE FREE SURVIVAL; GENETIC DATABASE; GENETICS; HUMAN CHROMOSOME; METABOLISM; MORTALITY; MULTICENTER STUDY; OVARY TUMOR; PATHOLOGY; SURVIVAL RATE;

DNA;

BREAST NEOPLASMS; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN; COHORT STUDIES; DATABASES, GENETIC; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; FEMALE; HUMANS; OVARIAN NEOPLASMS; SURVIVAL RATE;

EID: 84920448088     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.07.019     Document Type: Article

References (45)

1. Aparicio S., Caldas C. The implications of clonal genome evolution for cancer medicine. N.Engl. J. Med. 2013, 368:842-851. 10.1056/NEJMra1204892.
2. Bengtsson H., Wirapati P., Speed T.P. A single-array preprocessing method for estimating full-resolution raw copy numbers from all affymetrix genotyping arrays including GenomeWideSNP 5 & 6. Bioinformatics 2009, 25:2149-2156. 10.1093/bioinformatics/btp371.
3. Beroukhim R., Mermel C.H., Porter D., Wei G., Raychaudhuri S., Donovan J., Barretina J., Boehm J.S., Dobson J., Urashima M., Mc Henry K.T., Pinchback R.M., Ligon A.H., Cho Y.-J., Haery L., Greulich H., Reich M., Winckler W., Lawrence M.S., Weir B.A., Tanaka K.E., Chiang D.Y., Bass A.J., Loo A., Hoffman C., Prensner J.R., Liefeld T., Gao Q., Yecies D., Signoretti S., Maher E., Kaye F.J., Sasaki H., Tepper J.E., Fletcher J.A., Tabernero J., Baselga J., Tsao M.-S., Demichelis F., Rubin M.A., Janne P.A., Daly M.J., Nucera C., Levine R.L., Ebert B.L., Gabriel S., Rustgi A.K., Antonescu C.R., Ladanyi M., Letai A., Garraway L.A., Loda M., Beer D.G., True L.D., Okamoto A., Pomeroy S.L., Singer S., Golub T.R., Lander E.S., Getz G., Sellers W.R., Meyerson M. The landscape of somatic copy-number alteration across human cancers. Nature 2010, 463:899-905. 10.1038/nature08822.
4. Blows F.M., Driver K.E., Schmidt M.K., Broeks A., van Leeuwen F.E., Wesseling J., Cheang M.C.U., Gelmon K., Nielsen T.O., Blomqvist C., Heikkilä P., Heikkinen T., Nevanlinna H.A., Akslen L.A., Bégin L.R., Foulkes W.D., Couch F.J., Wang X., Cafourek V., Olson J.E., Baglietto L., Giles G.G., Severi G., McLean C.A., Southey M.C., Rakha E., Green A.R., Ellis I.O., Sherman M.E., Lissowska J., Anderson W.F., Cox A., Cross S.S., Reed M.W.R., Provenzano E., Dawson S.-J., Dunning A.M., Humphreys M.K., Easton D.F., Garcia-Closas M., Caldas C., Pharoah P.D., Huntsman D.G. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010, 7:e1000279. 10.1371/journal.pmed.1000279.
5. Borgan E., Navon R., Vollan H.K.M., Schlichting E., Sauer T., Yakhini Z., Lingjaerde O.C., Sørlie T., Børresen-Dale A.-L. Ischemia caused by time to freezing induces systematic microRNA and mRNA responses in cancer tissue. Mol. Oncol. 2011, 10.1016/j.molonc.2011.08.004.
6. Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615. 10.1038/nature10166.
7. Cardoso F., Piccart-Gebhart M., van't Veer L.J., Rutgers E., TRANSBIG Consortium The MINDACT trial: the first prospective clinical validation of a genomic tool. Mol. Oncol. 2007, 1:246-251. 10.1016/j.molonc.2007.10.004.
8. Cardoso F., van't Veer L.J., Rutgers E., Loi S., Mook S., Piccart-Gebhart M.J. Clinical application of the 70-gene profile: the MINDACT trial. J.Clin. Oncol. 2008, 26:729-735. 10.1200/JCO.2007.14.3222.
9. Curtis C., Shah S.P., Chin S.-F., Turashvili G., Rueda O.M., Dunning M.J., Speed D., Lynch A.G., Samarajiwa S.A., Yuan Y., Gräf S., Ha G., Haffari G., Bashashati A., Russell R., McKinney S., Langerød A., Green A., Provenzano E., Wishart G.C., Pinder S.E., Watson P., Markowetz F., Murphy L., Ellis I., Purushotham A., Børresen-Dale A.-L., Brenton J.D., Tavaré S., Caldas C., Aparicio S. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012, 486:346-352. METABRIC Group. 10.1038/nature10983.
10. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). 10.1016/S0140-6736(05)66544-0.
11. Etemadmoghadam D., DeFazio A., Beroukhim R., Mermel C., George J., Getz G., Tothill R., Okamoto A., Raeder M.B., Harnett P., Lade S., Akslen L.A., Tinker A.V., Locandro B., Alsop K., Chiew Y.-E., Traficante N., Fereday S., Johnson D., Fox S., Sellers W.R., Urashima M., Salvesen H.B., Meyerson M., Bowtell D.D.L. Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin. Cancer Res. 2009, 15:1417-1427. AOCS Study Group. 10.1158/1078-0432.CCR-08-1564.
12. Gentleman R.C., Carey V.J., Bates D.M., Bolstad B., Dettling M., Dudoit S., Ellis B., Gautier L., Ge Y., Gentry J., Hornik K., Hothorn T., Huber W., Iacus S., Irizarry R., Leisch F., Li C., Maechler M., Rossini A.J., Sawitzki G., Smith C., Smyth G.K., Tierney L., Yang J.Y.H., Zhang J. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004, 5:R80. 10.1186/gb-2004-5-10-r80.
13. Goldhirsch A., Ingle J.N., Gelber R.D., Coates A.S., Thurlimann B., Senn H.J., Panel members Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann. Oncol.: Official Journal of the European Society for Medical Oncology/ESMO 2009, 1319-1329. Presented at the. 10.1093/annonc/mdp322.
14. Halabi S., Small E.J., Kantoff P.W., Kattan M.W., Kaplan E.B., Dawson N.A., Levine E.G., Blumenstein B.A., Vogelzang N.J. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J.Clin. Oncol. 2003, 21:1232-1237.
15. Hall P.S., McCabe C., Stein R.C., Cameron D. Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer. J.Natl. Cancer Inst. 2012, 104:56-66. 10.1093/jnci/djr484.
16. Harrell F.E. Regression Modeling Strategies 2001, Springer Verlag.
17. Harrell F.E. rms: Regression Modeling Strategies 2014, R package version 4.1-3. http://CRAN.R-project.org/package=rms.
18. Harrell F.E., Lee K.L., Mark D.B. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat. Med. 1996, 15:361-387. 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4.
19. Hicks J.B., Krasnitz A., Lakshmi B., Navin N.E., Riggs M., Leibu E., Esposito D., Alexander J., Troge J., Grubor V., Yoon S., Wigler M., Ye K., Børresen-Dale A.-L., Naume B., Schlichting E., Norton L., Hägerström T., Skoog L., Auer G., Månér S., Lundin P., Zetterberg A. Novel patterns of genome rearrangement and their association with survival in breast cancer. Genome Res. 2006, 16:1465-1479. 10.1101/gr.5460106.
20. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60:277-300. 10.3322/caac.20073.
21. Koonings P.P., Campbell K., Mishell D.R., Grimes D.A. Relative frequency of primary ovarian neoplasms: a 10-year review. Obstet. Gynecol. 1989, 74:921-926.
22. Lehmann B.D., Bauer J.A., Chen X., Sanders M.E., Chakravarthy A.B., Shyr Y., Pietenpol J.A. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J.Clin. Invest. 2011, 121. 10.1172/JCI45014.
23. Lynch A.G., Chin S.-F., Dunning M.J., Caldas C., Tavaré S., Curtis C. Calling sample mix-ups in cancer population studies. PLoS ONE 2012, 7:e41815. 10.1371/journal.pone.0041815.
24. McShane L.M., Altman D.G., Sauerbrei W., Taube S.E., Gion M., Clark G.M. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br. J. Cancer 2005, Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. 10.1038/sj.bjc.6602678.
25. Nilsen G., Liestøl K., Van Loo P., Vollan H.K.M., Eide M.B., Rueda O.M., Chin S.-F., Russell R., Baumbusch L.O., Caldas C., Børresen-Dale A.-L., Lingjærde O.C. Copynumber: efficient algorithms for single- and multi-track copy number segmentation. BMC Genomics 2012, 10.1186/1471-2164-13-591.
26. Ozols R.F. Update of the NCCN ovarian cancer practice guidelines. Oncology (Williston Park, N.Y.) 1997, 11:95-105.
27. Paik S., Shak S., Tang G., Kim C., Baker J., Cronin M., Baehner F.L., Walker M.G., Watson D., Park T., Hiller W., Fisher E.R., Wickerham D.L., Bryant J., Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N.Engl. J. Med. 2004, 351:2817-2826. 10.1056/NEJMoa041588.
28. Pencina M.J., D'Agostino R.B., Steyerberg E.W. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat. Med. 2011, 30:11-21. 10.1002/sim.4085.
29. Pencina M.J., D'Agostino R.B., Vasan R.S. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat. Med. 2008, 27:157-172. Discussion 207-12. 10.1002/sim.2929.
30. Perou C.M., Sørlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., Fluge O., Pergamenschikov A., Williams C., Zhu S.X., Lønning P.E., Børresen-Dale A.-L., Brown P.O., Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752. 10.1038/35021093.
31. Ravdin P.M., Siminoff L.A., Davis G.J., Mercer M.B., Hewlett J., Gerson N., Parker H.L. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J.Clin. Oncol. 2001, 19:980-991.
32. Russnes H.G., Vollan H.K.M., Lingjaerde O.C., Krasnitz A., Lundin P., Naume B., Sørlie T., Borgen E., Rye I.H., Langerød A., Chin S.-F., Teschendorff A.E., Stephens P.J., Månér S., Schlichting E., Baumbusch L.O., Kåresen R., Stratton M.R., Wigler M., Caldas C., Zetterberg A., Hicks J.B., Børresen-Dale A.-L. Genomic architecture characterizes tumor progression paths and fate in breast cancer patients. Sci. Transl. Med. 2010, 2:38ra47. 10.1126/scitranslmed.3000611.
33. Rutgers E., Piccart-Gebhart M.J., Bogaerts J., Delaloge S., Veer L.V., Rubio I.T., Viale G., Thompson A.M., Passalacqua R., Nitz U., Vindevoghel A., Pierga J.-Y., Ravdin P.M., Werutsky G., Cardoso F. The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase. Eur. J. Cancer 2011, 47:2742-2749. 10.1016/j.ejca.2011.09.016.
34. Seidman J.D., Horkayne-Szakaly I., Haiba M., Boice C.R., Kurman R.J., Ronnett B.M. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int. J. Gynecol. Pathol. 2004, 23:41-44. 10.1097/01.pgp.0000101080.35393.16.
35. Sparano J.A. TAILORx: trial assigning individualized options for treatment (Rx). Clin. Breast Cancer 2006, 7:347-350. 10.3816/CBC.2006.n.051.
36. Sparano J.A., Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J.Clin. Oncol. 2008, 26:721-728. 10.1200/JCO.2007.15.1068.
37. Sørlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Thorsen T., Quist H., Matese J.C., Brown P.O., Botstein D., Eystein Lønning P., Børresen-Dale A.-L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:10869-10874. 10.1073/pnas.191367098.
38. Sørlie T., Tibshirani R., Parker J., Hastie T., Marron J.S., Nobel A.B., Deng S., Johnsen H., Pesich R., Geisler S., Demeter J., Perou C.M., Lønning P.E., Brown P.O., Børresen-Dale A.-L., Botstein D. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:8418-8423. 10.1073/pnas.0932692100.
39. van de Vijver M.J., He Y.D., van't Veer L.J., Dai H., Hart A.A.M., Voskuil D.W., Schreiber G.J., Peterse J.L., Roberts C., Marton M.J., Parrish M., Atsma D., Witteveen A., Glas A., Delahaye L., van der Velde T., Bartelink H., Rodenhuis S., Rutgers E.T., Friend S.H., Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N.Engl. J. Med. 2002, 347:1999-2009. 10.1056/NEJMoa021967.
40. van't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A.M., Mao M., Peterse H.L., van der Kooy K., Marton M.J., Witteveen A.T., Schreiber G.J., Kerkhoven R.M., Roberts C., Linsley P.S., Bernards R., Friend S.H. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536. 10.1038/415530a.
41. Winter W.E., Maxwell G.L., Tian C., Carlson J.W., Ozols R.F., Rose P.G., Markman M., Armstrong D.K., Muggia F., McGuire W.P. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J.Clin. Oncol. 2007, 25:3621-3627. Gynecologic Oncology Group Study. 10.1200/JCO.2006.10.2517.
42. Winter W.E., Maxwell G.L., Tian C., Sundborg M.J., Rose G.S., Rose P.G., Rubin S.C., Muggia F., McGuire W.P. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J.Clin. Oncol. 2008, 26:83-89. Gynecologic Oncology Group. 10.1200/JCO.2007.13.1953.
43. Wishart G.C., Azzato E.M., Greenberg D.C., Rashbass J., Kearins O., Lawrence G., Caldas C., Pharoah P.D. PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res. 2010, 12:R1. 10.1186/bcr2464.
44. Wishart G.C., Bajdik C.D., Azzato E.M., Dicks E., Greenberg D.C., Rashbass J., Caldas C., Pharoah P.D. A population-based validation of the prognostic model PREDICT for early breast cancer. Eur. J. Surg. Oncol. 2011, 37:411-417. 10.1016/j.ejso.2011.02.001.
45. Wishart G.C., Bajdik C.D., Dicks E., Provenzano E., Schmidt M.K., Sherman M., Greenberg D.C., Green A.R., Gelmon K.A., Kosma V.-M., Olson J.E., Beckmann M.W., Winqvist R., Cross S.S., Severi G., Huntsman D.G., Pylkäs K., Ellis I., Nielsen T.O., Giles G., Blomqvist C., Fasching P.A., Couch F.J., Rakha E., Foulkes W.D., Blows F.M., Bégin L.R., van't Veer L.J., Southey M., Nevanlinna H., Mannermaa A., Cox A., Cheang M., Baglietto L., Caldas C., Garcia-Closas M., Pharoah P.D. PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. Br. J. Cancer 2012, 107:800-807. 10.1038/bjc.2012.338.